Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau Jr., View ORCID ProfileSanjay Ramakrishnan, View ORCID ProfilePeter J Barnes, Jodie L Simpson, View ORCID ProfileSteven P Cass, View ORCID ProfileRichard EK Russell, Louise E Donnelly, View ORCID ProfileMona Bafadhel
doi: https://doi.org/10.1101/2021.10.26.21265512
Jonathan R Baker
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahdi Mahdi
2National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), United Kingdom
3Nuffield Department of Medicine, University of Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan V Nicolau Jr.
3Nuffield Department of Medicine, University of Oxford, United Kingdom
4UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia
5School of Mathematical Sciences, Queensland University of Technology, Brisbane 4000 Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Ramakrishnan
2National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), United Kingdom
3Nuffield Department of Medicine, University of Oxford, United Kingdom
6School of Medical and Health Sciences, Edith Cowan University, Perth, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sanjay Ramakrishnan
Peter J Barnes
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter J Barnes
Jodie L Simpson
7School of Medicine and Public Health, Priority Centre for Healthy Lungs, University of Newcastle, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven P Cass
2National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), United Kingdom
3Nuffield Department of Medicine, University of Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven P Cass
Richard EK Russell
2National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), United Kingdom
3Nuffield Department of Medicine, University of Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard EK Russell
Louise E Donnelly
1National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona Bafadhel
2National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), United Kingdom
3Nuffield Department of Medicine, University of Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mona Bafadhel
  • For correspondence: mona.bafadhel@ndm.ox.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Vaccinations against SARS-CoV-2 are effective in COVID-19. However, with limited vaccine access, vaccine hesitancy and variant breakthroughs, there is still a need for effective and safe early treatments. Two community-based clinical trials of the inhaled corticosteroid, budesonide, have recently been published showing and improvement in patients with COVID-19 treated early with budesonide1,2. To understand mechanistically how budesonide was beneficial, inflammatory mediators were assessed in the nasal mucosa of patients recruited to the Steroids in COVID (STOIC1) trial and a cohort of SARS-CoV-2 negative individuals. Here we show that in early COVID-19, elevation in viral response proteins and Th1 and Th2 inflammation occurs. Longitudinal sampling in the natural course of COVID-19 showed persistently high interferon levels and elevated concentrations of the eosinophil chemokine, CCL11. In patients who deteriorate, the initial nasal mucosal signal is characterised by a marked suppression of the early inflammatory response, with reduced concentrations of interferon and inflammatory cytokines, but elevated eosinophil chemokines. Systemic inflammation remained altered in COVID-19 patients, implying that even after symptom resolution, changes in immunological mediators do not resolve. Budesonide treatment decreased IL-33 and IFN-γ, implying a reduction in epithelial damage and dampening of the interferon response. Budesonide treatment also increased CCL17 concentrations, suggesting an improved T-cell response; and significantly alters inflammatory pathways giving further insight into how this treatment can accelerate patient recovery.

Figure
  • Download figure
  • Open in new tab

Competing Interest Statement

JRB, SPC, MM, DVN, and JSL have no competing interests to declare. SR reports grants and non financial support from Oxford Respiratory NIHR BRC during the conduct of the study; non-financial support from AstraZeneca, personal fees from Australian Government Research Training Program outside the submitted work. LED reports grants from AstraZeneca, from Boehringer-Ingelheim, outside the submitted work. PJB reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Teva, personal fees from Covis during the conduct of the study. REKR reports grants from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi UK, personal fees from Glaxo-SmithKline during the conduct of the study. MB reports grants from AstraZeneca, personal fees from AstraZeneca, Chiesi, GSK, other from Albus Health, ProAxsis, outside the submitted work.

Funding Statement

The study was funded by the Oxford NIHR Biomedical Research Centre and AstraZeneca (Gothenburg Sweden). The funders had no role in study design, data collection, data analysis or the decision to publish. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The National Health Service/Health Research Authority UK Fulham London Research Ethics Committee gave ethical approval for this work (20/HRA/2531)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and analysed during the current study are available from the corresponding author on reasonable request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19
Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau Jr., Sanjay Ramakrishnan, Peter J Barnes, Jodie L Simpson, Steven P Cass, Richard EK Russell, Louise E Donnelly, Mona Bafadhel
medRxiv 2021.10.26.21265512; doi: https://doi.org/10.1101/2021.10.26.21265512
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19
Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau Jr., Sanjay Ramakrishnan, Peter J Barnes, Jodie L Simpson, Steven P Cass, Richard EK Russell, Louise E Donnelly, Mona Bafadhel
medRxiv 2021.10.26.21265512; doi: https://doi.org/10.1101/2021.10.26.21265512

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)